William A. Canfield

William A. Canfield was a prominent glycobiologist and the founder of Novazyme, a biotechnology company based in Oklahoma City. His groundbreaking research focused on developing enzyme therapies, notably for Pompe disease, a rare genetic disorder. Canfield's work in this field began in 1998 and culminated in the creation of an enzyme that could stabilize the condition, marking a significant advancement in treatment options for affected individuals. In 2001, Novazyme was acquired by Genzyme, further validating Canfield's contributions to biotechnology and medicine. After his tenure at Genzyme, Canfield continued his commitment to scientific innovation by co-founding Cytovance Biologics. He played a crucial role in rescuing the company from bankruptcy in 2005 by successfully raising $9 million through an investor group, demonstrating his leadership and dedication to advancing biopharmaceutical research. Canfield's legacy lies in his contributions to glycobiology and his impact on the development of therapies for rare diseases, solidifying his status as a key figure in the biotechnology sector.